Market News & Trends
Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved With Potential First-in-Class Oral Treatment for PKU
Jnana Therapeutics recently announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor…
Oxford Biomedica Completes Acquisition of ABL Europe
The acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica’s position as a world-leading cell and gene therapy CDMO. This strategic move broadens….
Longeveron Receives Notice of US Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B
Longeveron Inc. recently announced it received a notice of patent allowance from the United States Patent and Trademark Office (PTO) for Medicinal Signaling Cells (MSCs),…
First Patient Dosed With LIXTE’s LB-100 & GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
LIXTE Biotechnology Holdings, Inc. recently announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s…
GDMC Secures $21-Million Growth Capital Funding to Expand Global Genetic Medicines Design & Manufacturing Operations
Genetic Design and Manufacturing Corporation (GDMC) recently announced a Series A funding of $21 million. The funding round is led by Celadon Partners, an Asia…
Repare Therapeutics Announces Achievement of $40-Million Roche Clinical Milestone Payment
Milestone payment triggered by dosing of the first patient in camonsertib-based arm in Roche’s Phase 2 TAPISTRY platform clinical trial….
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients With Advanced Cancer Resulting in Recommended Phase 2 Doses
Processa Pharmaceuticals, Inc. recently announced the successful completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (NGC-Cap). From the…
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients With Rheumatoid Arthritis
Incannex Healthcare Inc. recently announced patient dosing has commenced in the Phase 2 clinical trial assessing IHL-675A in patients with rheumatoid arthritis (RA). IHL-675A is…
Evaxion to Develop Tailored Novel Cancer Vaccines Based Upon a New Untapped Source of AI-Discovered Targets
Evaxion Biotech A/S recently announced an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses…
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
Silo Pharma, Inc. recently announced its Alzheimer’s disease therapeutic SPC-14 showed positive efficacy in small animals. Data from a study conducted at Columbia University in collaboration…
Recipharm, Medspray & Resyca Enter Exclusive License Agreement to Develop Nasally Delivered Drug Products Using Proprietary Soft Mist Technology
Recipharm recently announced an exclusive license and collaboration agreement with Medspray and Resyca to develop soft mist nasal delivery devices for single and combination drug products. This collaboration….
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
Ensysce Biosciences, Inc. recently announced receipt of notice from the US FDA that it has granted Breakthrough Therapy Designation (BTD) for PF614-MPAR. A next-generation opioid, PF614-MPAR represents a major….
Micropore Appoints Insung Chroma-Tech Co as Korean Distributor
UK-based particle engineering specialist Micropore Technologies has just announced the appointment of Insung Chroma-Tech Co. as the distributor for its patented membrane technology in the…
Colorcon Launches a New Titanium Dioxide-Free, High Opacity PVA-Based Coating for Pharmaceutical Tablets
Colorcon recently announced the launch of a new Opadry titanium dioxide (TiO2)-free film coating system for pharmaceutical tablets. Annabel Bordmann, Film Coatings General Manager, said…
Biognosys Expands US Footprint With New Proteomics CRO Facility in Massachusetts
Biognosys recently announced the operational readiness of its new proteomics facility in Massachusetts. This US expansion facilitates access to select proteomics contract research organization (CRO) services for our US biopharma customers…..
Vivtex Enters Research Collaboration With Astellas Pharma
Vivtex Corporation recently announced it has entered a research collaboration with Astellas Pharma Inc., a global pharmaceutical company. The collaboration is focused on the evaluation…
Artelo Biosciences Announces Publication of New Peer-Reviewed Preclinical Research Demonstrating Effectiveness in Treating & Preventing Oxaliplatin-Induced Peripheral Neuropathy
Artelo Biosciences, Inc. recently announced new research published in the peer-reviewed Journal of Pain. The research article, titled Discovery and preclinical evaluation of a novel inhibitor…
Alcami Announces Acquisition of West-Coast Based Pacific Pharmaceutical Services
Alcami Corporation recently announced it has completed the acquisition of Pacific Pharmaceutical Services, Inc. (PPS), a preferred provider of….
Vaxxinity Announces Collaboration on Space Medicine Research With University of Central Florida
Vaxxinity, Inc. recently announced a collaboration with the University of Central Florida (UCF) to advance space medicine research. The research, funded by a grant from the…
Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis & Treatment of Cancer & Other Diseases
Akoya Biosciences, Inc. recently announced the newly established Queensland Spatial Biology Centre (QSBC), located in Brisbane, Australia, is using the PhenoCycler-Fusion spatial biology platform as…
